Research

Hormonal

Tirzepatide (up to 15 mg weekly) achieves the highest mean weight loss (up to 20.9%) among current pharmacotherapies but lacks FDA approval for cardiovascular risk reduction.

Tirzepatide (up to 15 mg weekly) offers the highest weight loss potential (up to 20.9%) among current drugs. However, it is not yet FDA-approved for cardiovascular risk reduction. Titrate the dose slowly to manage gastrointestinal side effects.

StrongSupportsVERY_HIGH confidence
Tirzepatide leads at 20.9%, though it lacks FDA approval for CV risk reduction or adolescent use [56]. In SURMOUNT-1... tirzepatide led to 15.0-20.9% weight loss vs. 3.1% with placebo over 72 weeks...
Prabhash Chand Manoria · Cureus · 2025

Why this rating

Supported by large RCTs (SURMOUNT-1, 2, 3, SUMMIT) with significant results.

Source

The Obesity Drug Revolution: New Frontiers in Pharmacotherapy

Prabhash Chand Manoria · Cureus · 2025

DOI 10.7759/cureus.96713

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →